CASI

CASI Pharmaceuticals, Inc.

6.01 USD
+0.50 (+9.07%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

CASI Pharmaceuticals, Inc. stock is down -4.45% since 30 days ago. The next earnings date is Apr 24, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 38.46% of the previous 12 March’s closed higher than February.

About CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. develops and commercializes therapeutics and pharmaceutical products. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-NHL)